Previous 10 | Next 10 |
NextCure press release (NASDAQ:NXTC): Q1 GAAP EPS of -$0.74 misses by $0.07. Cash, cash equivalents, and marketable securities, excluding restricted cash, as of March 31, 2022, were $201.3 million as compared with $219.6 million as of December 31, 2021 For further details see: NextCure ...
On track to report data from all three clinical programs in the second half of 2022 First quarter ending cash of $201.3 million expected to fund operations into the first quarter of 2024 BELTSVILLE, Md., May 05, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: N...
BELTSVILLE, Md., May 03, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will parti...
BELTSVILLE, Md., April 19, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the publication ...
BELTSVILLE, Md., April 05, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will pre...
Gainers: Incannex Healthcare (NASDAQ:IXHL) +28%, GitLab (NASDAQ:GTLB) +12%, NextCure (NASDAQ:NXTC) +5%, Cyxtera Technologies (NASDAQ:CYXT) +4%, Grindrod Shipping (NASDAQ:GRIN) +4%. Losers: Coupa Software (NASDAQ:COUP) -27%, DLocal (NASDAQ:DLO) -13%, Mesa Air (NASDAQ:MESA) -3%, Aurora Inn...
NextCure press release (NASDAQ:NXTC): FY GAAP EPS of -$2.51. FY cash equivalents $219.5M For further details see: NextCure GAAP EPS of -$2.51
Multiple data readouts expected in 2022, including updates for all three clinical programs Ends 2021 with cash position of $219.6 million that is expected to fund operations into first quarter of 2024 BELTSVILLE, Md., March 03, 2022 (GLOBE NEWSWIRE) -- NextCure,...
The following slide deck was published by NextCure, Inc. in conjunction with this event. For further details see: NextCure (NXTC) Presents At Global Healthcare Virtual Conference - Slideshow
BELTSVILLE, Md., Feb. 08, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will pres...
News, Short Squeeze, Breakout and More Instantly...
BELTSVILLE, Md., June 20, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies, today announced that it will present and host institutional investor meetings...
Of the evaluable ICI-naïve MSS/MSI-L CRC patients without liver metastasis, there were 2 confirmed ongoing PRs and a disease control rate of 51% Of the 7 evaluable ovarian cancer patients, there were 3 PRs and a disease control rate of 43% Data to be presented June 1, 2024,...
Phase 1b data for NC410 combo with pembro to be presented at ASCO annual meeting on June 1 Presented preclinical data from LNCB74 (B7-H4 ADC) at recent AACR annual meeting Cash of approximately $96.0 million expected to fund operations into second half of 2026 BELTSVILLE...